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Abstract
Muscle-eye-brain disease (MEB) and Walker Warburg Syndrome (WWS) belong to a spectrum of autosomal recessive
diseases characterized by ocular dysgenesis, neuronal migration defects, and congenital muscular dystrophy. Until now, the
pathophysiology of MEB/WWS has been attributed to alteration in dystroglycan post-translational modification. Here, we
provide evidence that mutations in a gene coding for a major basement membrane protein, collagen IV alpha 1 (COL4A1),
are a novel cause of MEB/WWS. Using a combination of histological, molecular, and biochemical approaches, we show that
heterozygous Col4a1 mutant mice have ocular dysgenesis, neuronal localization defects, and myopathy characteristic of
MEB/WWS. Importantly, we identified putative heterozygous mutations in COL4A1 in two MEB/WWS patients. Both
mutations occur within conserved amino acids of the triple-helix-forming domain of the protein, and at least one mutation
interferes with secretion of the mutant proteins, resulting instead in intracellular accumulation. Expression and
posttranslational modification of dystroglycan is unaltered in Col4a1 mutant mice indicating that COL4A1 mutations
represent a distinct pathogenic mechanism underlying MEB/WWS. These findings implicate a novel gene and a novel
mechanism in the etiology of MEB/WWS and expand the clinical spectrum of COL4A1-associated disorders.
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Introduction
Congenital muscular dystrophies (CMDs) involving ocular and
cerebral malformations are devastating childhood diseases.
Fukuyama congenital muscular dystrophy, Muscle-Eye-Brain
disease (MEB), and Walker-Warburg Syndrome (WWS) are
clinically and mechanistically related forms of CMD [1–4].
Patients present at birth or as infants with muscle weakness,
hypotonia or even severe myopathy leading to fatal respiratory
insufficiency. Clinical presentation varies between patients but
often includes myofiber necrosis and fibrosis, replacement by
adipose tissue, split muscle fibers and the presence of non-
peripheral nuclei. In addition, while most patients exhibit marked
elevation of serum creatine kinase (CK), others have CK levels
within the normal range [5].
Ocular and cerebral phenotypes demonstrate variable pene-
trance and expressivity between individual patients. For instance,
ocular dysgenesis can occur in either, or both, the anterior (Peters’
anomaly, Rieger syndrome, cataracts, buphthalmos and develop-
mental glaucoma) and posterior portions of the eye (retinal
dysplasia, retinal detachments and optic nerve hypoplasia) [6–8].
Variable neurological manifestations, including mental retardation
and epilepsy, may be at least partially explained by cerebral
cortical malformations including cobblestone lissencephaly, cere-
bellar hypoplasia, hydrocephalus and encephalocele.
Genetic and biochemical studies led to the identification of a
number of genes involved in the etiology of CMDs and revealed
that alterations in post-translational processing of dystroglycan
underlie MEB/WWS [9–15]. In these ‘dystroglycanopathies’,
hypoglycosylation of dystroglycan disrupts ligand binding and
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Central nervous system pathology is proposed to be secondary to
defective interactions between radial glial cells and the pial
basement membrane [16–18]. Despite these major advances,
over half of MEB/WWS patients do not have mutations in
known genes encoding glycosyltransferases [19,20], suggesting
that other genes in this pathway contribute to disease or that
independent mechanisms are responsible. Identifying new
pathways involved in MEB/WWS will be an important
breakthrough that could open new avenues for understanding
and ultimately treating CMDs.
We have recently discovered the first mutations in the gene
coding for the ubiquitous basement membrane protein type IV
collagen alpha 1 in mice (Col4a1) and humans (COL4A1) [21].
COL4A1 is the most abundant basement membrane protein and
is ubiquitously present in basement membranes with few
exceptions. The collagenous domain (a long stretch of Gly-Xaa-
Yaa repeats that forms a triple helix) accounts for over 90% of the
protein. Mutations in this triple helix-forming domain are well
documented to be pathogenic in several types of collagens,
including type IV collagens. The mutation we identified in mice
(referred to as Col4a1
Dex40) disrupts a splice acceptor site, causing
exon 40 to be skipped and concomitant deletion of 17 amino
acids from the collagen triple helical domain which interferes
with proper folding, assembly and secretion of heterotrimeric
COL4A1 and COL4A2 [21,22]. To date, eleven out of twelve
other Col4a1 mutations reported in mice [23,24] and seventeen
out of twenty one COL4A1 mutations identified in humans
[21,22,25–34] are missense mutations within the triple helical
domain, demonstrating that alterations of this domain are highly
pathogenic.
In mice and humans, semi-dominant Col4a1/COL4A1 muta-
tions are highly pleiotropic with variable expressivity. The tissue
distribution and severity of pathology depends on genetic and
environmental factors but commonly include cerebrovascular
diseases, ocular and renal defects [21–24,35]. Here, we broaden
this spectrum to include MEB/WWS. We show that, depending
on the genetic context; Col4a1
+/Dex40 mice recapitulate the
pathophysiological hallmarks of MEB/WWS, including ocular
anterior segment dysgenesis, optic nerve hypoplasia, cortical
lamination defects and myopathy. In addition, we identify
heterozygous mutations in the triple–helix-forming domain of
COL4A1 in two MEB/WWS patients. Together, these findings
support COL4A1 mutations as a novel genetic cause of MEB/
WWS. Importantly, COL4A1 is not directly related to post-
translational modification of dystroglycan. We show that the
mechanism is independent of dystroglycan glycosylation and
instead is probably due to decreased COL4A1 levels in basement
membranes. COL4A1 mutations are pleiotropic and these data
describe another clinically distinct group of diseases that can result
from alterations in a single gene.
Results
Mislocalization and increased apoptosis of retinal
ganglion cells cause optic nerve hypoplasia
Ocular hallmarks of MEB/WWS include anterior segment
dysgenesis and optic nerve hypoplasia. Depending on the genetic
context, mutations in Col4a1 can cause both anterior segment
dysgenesis and optic nerve hypoplasia although the underlying
pathogenic mechanism(s) remain unexplored [23,24,35]. During
development, COL4A1 is present in the inner limiting membrane
of the retina [36] and inner limiting membrane disruptions can
perturb retinal ganglion cell (RGC) localization and cause
apoptotic death [37]. To determine if excess RGC death during
development caused optic nerve hypoplasia, developing retinas
were immunolabeled for Islet-1 (ISL1) and Laminin, which mark
newly specified RGCs [38] and basement membranes, respec-
tively. At embryonic days (E) 14, E16 and E18, RGCs were
located in the innermost part of the retina in Col4a1
+/+ mice, with
only occasional ISL1 immunoreactivity detected in the outer
retina (Figure 1D). In contrast, in Col4a1
+/Dex40 mice, the
thickness of the ISL1 positive layer was highly variable and there
were more displaced ISL1 positive cells detected in the outer
retina (arrows in Figure 1H and 1L). Laminin immunoreactivity
revealed focal disruptions in the inner limiting membranes of
Col4a1
+/Dex40animals (asterisksin Figure1F) that were not observed
in Col4a1
+/+ animals. Moreover, in contrast to Col4a1
+/+
eyes where the vasculature is closely associated with the inner
limiting membrane, the hyaloid vasculature in Col4a1
+/Dex40 eyes is
most often found in the vitreous (Figure 1B and 1F) and, in one
extreme case, the posterior chamber was devoid of detectable
vasculature (Figure 1J).
During normal retinal development, approximately 50% of
RGCs undergo programmed cell death as the visual system
matures [39,40]. Induced or genetic disruption of the inner
limiting membrane perturbs RGC localization and leads to RGC
apoptosis during embryogenesis [37]. Therefore, we hypothesized
that Col4a1
+/Dex40 mice might exhibit increased RCG apoptosis.
To test this, we co-labeled retinal sections with antibodies against
ISL1 and activated Caspase-3 (Figure 2A–2F) and calculated the
apoptotic index by counting the number of ISL1/Caspase 3
double-labeled cells (Figure 2G). As retinas from Col4a1
+/Dex40
mice were smaller than retinas from Col4a1
+/+ mice (Figure 2H),
we normalized the number of double-labeled cells to the retinal
cross-sectional area. Col4a1
+/+ mice had low levels of ganglion cell
apoptosis at E14 and E16 that increased approximately 2-fold by
E18. Although apoptotic rates in Col4a1
+/Dex40 mice at E14 and
E16 were not significantly different from those observed in
Col4a1
+/+ mice, there was a significant increase in apoptosis of
ISL1 positive cells in Col4a1
+/Dex40 eyes compared to Col4a1
+/+
eyes at E18 (p,0.05) – especially among mislocalized ISL1 labeled
cells (Figure 2F). Of note, one E18 Col4a1
+/Dex40 eye had an
Author Summary
Muscle-eye-brain disease (MEB) and Walker-Warburg
Syndrome (WWS) are devastating childhood diseases that
belong to a subgroup of congenital muscular dystrophies
(CMDs) characterized by ocular dysgenesis, neuronal
migration defects, and congenital myopathy. Genetic
studies have revealed a number of genes involved in the
etiology of CMDs, and subsequent studies show that
alterations in dystroglycan glycosylation underlie MEB/
WWS. However, over half of MEB/WWS patients do not
have mutations in known genes encoding glycosyltrans-
ferases, suggesting that other genes are involved. Here, we
describe a novel and genetically complex mouse model for
MEB/WWS and identify putative heterozygous mutations
in COL4A1 in two MEB/WWS patients. We identify a novel
gene implicated in the etiology of MEB/WWS, provide
evidence of mechanistic heterogeneity for this subgroup
of congenital muscular dystrophies, and develop an assay
to test the functional significance of putative COL4A1
mutations. Our findings represent the first evidence for a
dominant mutation leading to MEB/WWS–like diseases
and expand the spectrum of clinical disorders resulting
from Col4a1/COL4A1 mutations.
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outlier and was removed from subsequent statistical analyses (see
Materials and Methods). Interestingly, we did not observe
vasculature in the posterior chamber of this eye suggesting that
retinal vasculature might directly contribute to the inner limiting
membrane or affect ganglion cell viability in other ways. Together,
Figure 1. Mislocalization of retinal ganglion cells in Col4a1
+/Dex40 eyes. Representative position-matched transverse sections from Col4a1
+/+
(A–D) and Col4a1
+/Dex40 (E–L) eyes at E18 labeled with anti-ISL1 (green in A, E, and I), anti-laminin (red in B, F and J) and DAPI (blue in C, G, and K).
Anti-ISL1 labeling revealed an increased number of RGCs in the outer retinas (arrows in D, H and L) of the mutant eyes. Labeling with anti-laminin
antibody revealed focal disruptions in the inner limiting membrane in Col4a1
+/Dex40 mice (asterisks in F) and demonstrates that the retinal vasculature
is adjacent to the inner limiting membrane in Col4a1
+/+ eyes but not in Col4a1
+/Dex40 eyes (arrowheads in B and F). Notably, in one extreme case, we
detected no hyaloid vasculature and markedly reduced retinal thickness in the eye shown in I–L. Scale bar: 50 mm.
doi:10.1371/journal.pgen.1002062.g001
Figure 2. Increased apoptosis of Islet-1 positive retinal ganglion cells in Col4a1
+/Dex40 eyes. Representative eye sections from E18 Col4a1
+/+
mice (A–C) and Col4a1
+/Dex40 mice (D–F) co-labeled with anti-ISL1 (green in A and D) and anti-activated Caspase-3 (red in B and E). Co-labeling for ISL1
and Caspase-3 revealed an increase in the number of apoptotic retinal ganglion cells in Col4a1
+/Dex40 eyes. Col4a1
+/Dex40 eyes were significantly
smaller than Col4a1
+/+ eyes at all ages examined (H; E14 p=0.01; E16 p=0.04; E18 p,10
25 comparing at least 6 eyes for Col4a1
+/+ (blue) and
Col4a1
+/Dex40 (red) at each age). After correcting for size, there was a significant increase in the number of apoptotic retinal ganglion cells in
Col4a1
+/Dex40 eyes at E18 (G; p=0.02 comparing at least 6 eyes for Col4a1
+/+ (blue) and Col4a1
+/Dex40 (red) at each age). In G and H, data are presented
as mean +/2 SEM. Scale bar: 50 mm.
doi:10.1371/journal.pgen.1002062.g002
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the inner limiting membrane and that optic nerve hypoplasia
results both from reduced production of retinal neurons and from
mislocalization and subsequent apoptosis of ganglion cells during
development.
Col4a1
+/Dex40 mice display cerebral cortical
malformations and cerebral neuronal localization defects
characteristic of cobblestone lissencephaly
Based on our observations in the retina, we predicted that
Col4a1
+/Dex40 mice might also show pial basement membrane
disruptions and cerebral cortical lamination defects that model
cobblestone lissencephaly seen in MEB/WWS. To test our
hypothesis, we stained coronal brain sections from adult
Col4a1
+/+ and Col4a1
+/Dex40 mice with cresyl violet and detected
abnormalities in all of the Col4a1
+/Dex40 but none of the Col4a1
+/+
mice examined (Figure 3). All Col4a1
+/Dex40 mice had focal and
variable cerebral cortex lamination defects ranging from mild
distortions and ectopias to severe heterotopic regions devoid of
obvious lamination (Figure 3B–3F). Occasionally, Col4a1
+/Dex40
mice displayed enlarged ventricles or major structural abnormal-
ities (Figure 3G and 3H). Immunolabeling with the pan–neuronal
marker NeuN confirmed the neuronal identity of the ectopic cells
(Figure 4). Col4a1
+/Dex40 mice also had subtle but consistent defects
within the hippocampus (Figure S1). The CA1, CA3 and dentate
gyrus layers of Col4a1
+/Dex40 mice were less tightly organized and
generally more dispersed compared to Col4a1
+/+ mice and local
perturbations were common. As it is the case in other animal
models of MEB/WWS [41,42], enhanced glial fibrillary acid
protein (GFAP) immunoreactivity, which is reflective of astrocytic
gliosis, was observed in the hippocampus and cerebral cortex of
Col4a1
+/Dex40 mice (Figure S2).
Neuronal localization defects in Col4a1
+/Dex40 mice are
congenital
To determine if cortical malformations were congenital or
acquired, we used bromodeoxyuridine (BrdU) pulse labeling in
utero to evaluate the localization of neurons that underwent
terminal cell division during defined stages of embryogenesis. The
locations of cells labeled at E14 or E16 were determined at birth
(P0). In all Col4a1
+/+ mice, BrdU-labeled neurons were uniformly
distributed primarily in the superficial cortex (Figure 5A and 5F).
In contrast, the distribution of BrdU-labeled cells in mutant
animals demonstrated that cortical lamination was disorganized.
Focal and variable lamination defects were completely penetrant
in Col4a1
+/Dex40 mice (Figure 5B–5E and 5G–5J). Laminin labeling
of basement membranes in P0 mice revealed discontinuous pial
basement membranes in all mutant mice, notably in areas
adjacent to ectopias (Figure 6). Together, these findings demon-
strate that Col4a1
+/Dex40 mice have abnormal neuronal localization
typical of cobblestone lissencephaly observed in MEB/WWS
patients and suggest that these congenital defects are secondary to
breaches in the pial basement membrane.
Genetically modifiable myopathy in Col4a1
+/Dex40 mice
Because Col4a1
+/ex40 mice display ocular and cerebral abnor-
malities characteristic of MEB/WWS, we hypothesized that they
would also have myopathy. To test this, we first confirmed that
COL4A1 was present in skeletal muscle basement membrane
by immunolabeling (Figure S3) and performed functional,
biochemical and histological analyses of muscles from young and
aged Col4a1
+/+ and Col4a1
+/Dex40 mice. At 3 months of age,
Col4a1
+/Dex40 mice performed significantly worse than controls in a
test of peak grip force (Figure 7A). Next, we analyzed serum CK
activity before and after exercise. We found no significant
difference in CK levels between control and mutant mice at
baseline, however, Col4a1
+/Dex40 mice had a significant elevation
in CK activity following exercise compared to pre-exercise
Col4a1
+/Dex40 and post-exercise Col4a1
+/+ mice (Figure 7B).
Consistent with these functional and biochemical data, we
also detected histological differences between Col4a1
+/+ and
Col4a1
+/Dex40 muscles. Compared to Col4a1
+/+ littermates,
Col4a1
+/Dex40 mice had occasional split muscle fibers and a
significant increase in the number of non-peripheral nuclei – a
measure of myopathy (Figure 7C–7E). Importantly, the severity of
myopathy was not markedly affected by age.
We have shown previously that ocular dysgenesis is genetic
context–dependent and that mutant F1 progeny of C57BL/6J and
CAST/EiJ crosses (CASTB6F1) are morphologically rescued [35].
As shown in Figure 7C, in contrast to what is observed on the
C57BL/6J background, the number of non-peripheral nuclei was
not increased in CASTB6F1 Col4a1
+/Dex40 mice compared to their
Figure 3. Col4a1
+/Dex40 mice have focal and variable cortical
malformations. Representative cresyl violet stained coronal brain
sections from adult Col4a1
+/+ (A) and Col4a1
+/Dex40 (B–H) revealed
cortical malformations characteristic of cobblestone lissencephaly in all
mutant brains examined (n=6). In contrast to the well-defined cortical
lamination observed in Col4a1
+/+ brains, Col4a1
+/Dex40 brains had
variable abnormalities including disorganized cortical lamination
(bracket in B), ectopias (C, enlarged in D), heterotopic regions (E and
F), enlarged ventricles (G) and, occasionally, severe cortical malforma-
tions (H). Scale bars: A–C and E–H, 800 mm; d, 200 mm.
doi:10.1371/journal.pgen.1002062.g003
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+/+ littermates. Moreover, there were significantly fewer
muscle fibers with non-peripheral nuclei in CASTB6F1
Col4a1
+/Dex40 mice compared to C57BL/6J Col4a1
+/Dex40 mice
(p,0.05), indicating that the CAST/EiJ strain has one or more
loci that can also ameliorate Col4a1-induced myopathy.
Identification of COL4A1 mutations in human MEB/WWS
patients
Col4a1
+/Dex40 mice display multiple hallmarks of MEB/WWS
raising the possibility that COL4A1 mutations might cause CMD-
like diseases in human patients. To test this, we performed direct
sequence analysis of genomic DNA from a cohort of 27 patients
with CMD (see Table S1 for primers). Fifteen patients had
diagnoses of WWS, two had diagnoses of MEB, and nine were not
specifically classified as either but had CMD with variable ocular
and cerebral involvement. To enrich for patients that may have
dominant or semi-dominant mutations, rather than recessive
mutations, most of the patients (23 out of 27) were chosen from
non-consanguineous families. Finally, all patients were negative for
mutations in genes currently known to underlie MEB/WWS-like
diseases including LARGE, POMT1, POMT2, POMGNT1, FKTN
and FKRP.
We identified several coding and non-coding sequence variants
in COL4A1 (Tables S2, S3, S4). Twelve coding variants were silent
and were either observed in controls or were not predicted to be
splice–site-altering variants [43]. We identified four non-synony-
mous coding variants. Two of the four non-synonymous variants
were previously identified SNPs that were highly polymorphic in
patients and in controls and therefore deemed unlikely to be
pathogenic. The two remaining SNPs were rare, missense variants
that have not been previously reported in dbSNP and were
heterozygous in independent patients. The first mutation was
identified in a patient diagnosed with WWS that had lissenceph-
aly, hydrocephalus, Dandy-Walker malformation, optic nerve
hypoplasia and was hypotonic with CMD (see Figure S4 and Text
S1 for clinical details). An adenine to guanine transition (A3046G)
in exon 36 substituted a methionine residue for a valine residue
Figure 4. Col4a1
+/Dex40 mice display cortical neuronal localiza-
tion defects. Representative images of NeuN-labeled coronal brain
sections from adult Col4a1
+/+ (A and C) and Col4a1
+/Dex40 (B and D–F)
mice revealed heterotopic regions (asterisks in B and E) and ectopias
(arrows in B and D) in all mutant brains examined. NeuN labeling of
ectopic cells located in the marginal zone (F, enlarged from box in E)
confirmed their neuronal identity. Scale bars: A–E, 500 mm; F, 125 mm.
doi:10.1371/journal.pgen.1002062.g004
Figure 5. Focal and variable cortical neuronal localization
defects are developmental. Embryos pulsed-labeled with BrdU at
E14 were harvested at birth and BrdU was immunolabeled in position-
matched coronal brain sections of Col4a1
+/+ (A and F) and Col4a1
+/Dex40
mice (B–E and G–J). In contrast to Col4a1
+/+ controls, in which BrdU-
labeled cells are distributed in a uniform layer in the outer cortex, all
Col4a1
+/Dex40 brains had focal neuronal localization defects that ranged
in severity from diffuse cell layers to ectopias and severely disorganized
cortical lamination (note gradient of severity from B through E and from
G through J). Similar results were observed in embryos labeled at E16.
Scale bar: 500 mm.
doi:10.1371/journal.pgen.1002062.g005
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(p.M1016V) and was not detected in 282 control chromosomes
(Figure 8A).
The second mutation was identified in a patient with
unspecified CMD with ocular and cerebral involvement. The
patient had mild gyral abnormalities, hydrocephalus, retinal
dysplasia, seizures and elevated CK (see Figure S4 and Text S1
for clinical details). A cytosine to guanine transversion (C3946G) in
exon 44 substituted a glutamine residue for a glutamate residue
within the triple helical domain of the protein at amino acid
number 1316 (p.Q1316E) (Figure 8A). Although this cytosine to
guanine transversion was not detected in 286 control chromo-
somes, it was present in the paternal DNA.
Functional analysis of putative COL4A1 mutations
The first variant, COL4A1
M1016V, is a mutation of a methionine
residue in the Y position of the Gly-Xaa-Yaa repeat in the triple
helix-forming domain. This amino acid is highly conserved and
the analogous residue is a methionine in all vertebrate orthologues
analyzed (Figure 8B) and in the COL4A1 paralogues COL4A3
and COL4A5 (data not shown). Moreover, there is precedence for
a Y position methionine to valine mutation in COL4A5 causing
Alport syndrome [44]. The second variant, COL4A1
Q1316E,i sa
mutation of a glutamine in the Y position residue within the triple
helix-forming domain. This glutamine residue is conserved in most
vertebrates (Figure 8B). There is a strong preference for basic
residues in the Y position of the Gly-Xaa-Yaa repeat and the
mutation represents a substitution from a neutral amino acid to an
acidic amino acid. Pathogenic mutations within the collagenous
domain often perturb triple helix assembly and mutations in
regions of low thermal stability are predicted to be more disruptive
[45]. According to an algorithm that predicts collagen stability
[46], both mutations modestly reduce the thermal stability of their
respective region (Figure 8C) although the biological relevance of
this is equivocal.
Pathogenic mutations in the triple helix forming domain of
several types of collagens impair secretion of the collagen
heterotrimers and concomitantly, misfolded proteins accumulate
within cells. To assess the functional significance of the
COL4A1
M1016V and COL4A1
Q1316E mutations, we developed an
assay to test the impact of the mutant proteins in a human cell line.
We stably transfected HT1080 cells with wild–type or mutant
COL4A1 cDNAs and determined the relative levels of intracellular
and secreted COL4A1. To validate the assay, we tested the effect
of the COL4A1
G562E mutant allele that is established to cause
familial small vessel disease in human patients [22,26]. As we
predicted, when compared to HT1080 cells transfected with wild–
type COL4A1, significant intracellular accumulation of COL4A1
and concurrent decrease in secreted COL4A1 was observed in
cells transfected with the COL4A1
G562E mutant cDNA (Figure 8D).
The two putative pathogenic mutations were functionally tested
using the same assay. Overall, the ratio of secreted/intracellular
COL4A1 for the COL4A1
M1016V mutation was reduced, however
the results were variable (n=9) and did not reach statistical
significance. In contrast, and similar to the established CO-
L4A1
G562E mutation, the COL4A1
Q1316E mutation clearly impaired
COL4A1 secretion leading to intracellular accumulation
(p,0.001), supporting the hypothesis that the COL4A1
Q1316E
Figure 6. Col4a1
+/Dex40 mice have focal breaches of the pial basement membrane during development. Representative images of laminin
labeled (green) coronal brain sections from P0 Col4a1
+/+ (A–D) and Col4a1
+/Dex40 (E–L) revealed breaches of the pial basement membrane in mutant
animals. All sections of Col4a1
+/+ brains examined (A–D) showed intact pial membranes (higher magnifications in D). In contrast, position-matched
Col4a1
+/Dex40 brains display multiple focal disruptions of the pial basement membrane (arrows and asterisks in G and K) that are shown in higher
magnification in H, and L. Notably, the high magnification image in L shows ectopic cells (DAPI in blue) that have breached the pial membrane
adjacent to a disruption. Scale bars: A–C, E–G, and I–K, 500 mm; D, H and L, 50 mm.
doi:10.1371/journal.pgen.1002062.g006
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monomeric and heterotrimeric forms of COL4A1 suggests that the
COL4A1
G562E and COL4A1
Q1316E mutations impaired triple helix
assembly and/or stability.
The mechanism of Col4a1-induced disease is
independent of dystroglycan glycosylation
Biochemical analyses revealed that known MEB/WWS-causing
mutations act via hypoglycosylation of dystroglycan [11]. Al-
though COL4A1 is not directly involved in post-translational
dystroglycan modification, misfolded COL4A1
Dex40 proteins in
the endoplasmic reticulum (ER) might indirectly impair dystro-
glycan post-translational modification. Similarly, ER stress can
produce reactive oxygen species [47–50] and exposure to reactive
oxygen species can result in dystroglycan de–glycosylation [51].
Thus, Col4a1-induced pathogenesis might still act indirectly via
dystroglycan hypoglycosylation or de–glycosylation. To test for
alterations in dystroglycan expression and/or post-translational
processing, we performed Western blot analysis on wheat germ
agglutinin (WGA)-enriched skeletal muscle extracts and compared
the amount and mobility of a– and b– dystroglycan between
Col4a1
+/+ and Col4a1
+/Dex40 mice using a polyclonal b–dystrogly-
can antibody and the IIH6 a–dystroglycan antibody that
recognizes the fully glycosylated, functional form of a–dystrogly-
can [11]. Immunoreactivity to, and mobility of, the precursor
dystroglycan protein (WGA-unbound fraction) and a– and b–
dystroglycan (WGA-bound, glycoprotein enriched fraction) were
indistinguishable between Col4a1
+/+ and Col4a1
+/Dex40 mice
(Figure 9). Consistent with this finding, immunolabeling of muscle
sections for a– and b– dystroglycan showed similar expression
patterns in the sarcolemma membrane of Col4a1
+/+ and
Col4a1
+/Dex40 mice. These data indicate that dystroglycan
expression, localization and post-translational modification are
not altered in Col4a1
+/Dex40 mice and that myopathy arises via
disruption of the basal lamina.
Discussion
In this study, we show that COL4A1 mutations cause multiple
pathophysiological hallmarks of MEB/WWS in mice and possibly
MEB/WWS in human patients. Mice harboring a semi-dominant
Col4a1 mutation have ocular dysgenesis, cerebral cortical lamina-
tion defects and myopathy. Optic nerve hypoplasia results, at least
in part, from mislocalization and increased apoptosis of RGCs
during development. Cerebral cortical malformations range from
Figure 7. Col4a1
+/Dex40 mice have functional, biochemical, histological, and genetically–complex myopathy. (A) Comparison of the peak
grip force (mean +/2SEM) between Col4a1
+/+ (blue; n=7) and Col4a1
+/Dex40 (red; n=7) mice at 3 months of age revealed a significant reduction in
Col4a1
+/Dex40 mice (** indicates p,0.01). (B) Serum creatine kinase (CK) activity was compared (mean +/2SEM) between Col4a1
+/+ (blue; n=7) and
Col4a1
+/Dex40 (red; n=7) mice before (Pre) and after (Post) exercise (* indicates p,0.05 vs all other groups). (C–E) Comparison of non-peripheral nuclei
(arrows in D and E; mean +/2SEM in C) between Col4a1
+/+ (counting of 17830 fibers in 5 muscles from 4 mice) and Col4a1
+/Dex40 (counting of 13820
fibers in 4 muscles from 4 mice) mice (14 to 16 months old) revealed a significant increase in the number of non-peripheral nuclei in Col4a1
+/Dex40
mice on the C57BL/6J background (control mean=1.5%; mutant mean=5.2%; p,0.0005). This difference is modified by the genetic context. There
was no difference between Col4a1
+/+ and Col4a1
+/Dex40 CASTB6F1 mice and there was a significant rescue of non-peripheral nuclei in CAST/B6F1
Col4a1
+/Dex40 mice compared to C57BL/6J Col4a1
+/Dex40 mice (p,0.005). Scale bar: 100 mm.
doi:10.1371/journal.pgen.1002062.g007
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PLoS Genetics | www.plosgenetics.org 7 May 2011 | Volume 7 | Issue 5 | e1002062Figure 8. Identification of COL4A1 missense mutations in two human patients. Direct sequence analysis of patient DNA revealed two
heterozygous missense mutations (A, top panels) that were not found in control patients (A, bottom panels). (B) Protein sequence alignments with
multiple species indicate a very strong degree of conservation of the altered amino acid for both mutations. Methionine at position 1016 is conserved
in all species tested except for C. elegans and Drosophila where this amino acid is a lysine. Glutamine at position 1316 is also highly conserved and is
never a glutamate residue. (C) Triple helix thermal stability was calculated by amino acid sequence and is plotted for the length of the COL4A1
protein. Arrows indicate the positions for each mutation and the effects of the mutations on calculated thermal stability are indicated in red. (D) For
quantitative analysis of the ratio of secreted to intracellular mutant COL4A1 protein levels, values are expressed as percentage of the wild-type
COL4A1 ratio and are presented as mean +/2 SEM. Representative Western blot images for secreted and intracellular COL4A1 are shown below the
graph. Nine independent Western blot experiments were performed using 6 independent clones per mutation for this analysis, **P,0.01.
doi:10.1371/journal.pgen.1002062.g008
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Myopathy is mild, but consistent and significant, and is
exacerbated by exercise but not by age. Importantly, myopathy
was genetic background-dependent, which implies that in resistant
genetic contexts Col4a1- induced myopathy might not be detected
but that on permissive genetic backgrounds, myopathy could be
severe. Two out of 27 MEB/WWS patients tested had COL4A1
mutations and in at least one case the mutation interfered with
protein secretion. Moreover, unlike all other known causes of
MEB/WWS, the cellular mechanism underlying Col4a1-induced
pathology is independent of dystroglycan post-translational
modification.
Until now, the precise pathogenic mechanism resulting from
COL4A1 mutations in human patients was poorly characterized
and was only presumed to impair protein secretion and cause
intracellular accumulation. Here, we have established and
validated a cellular assay that demonstrates this effect. However,
the relative contribution of COL4A1 deficiency in the basement
membrane versus toxic intracellular accumulation to pathogenesis
is difficult to dissociate and other possible mechanisms exist.
Although the ratio of secreted to intracellular protein for the
COL4A1
M1016V mutation was not statistically different from wild–
type there was an overall reduction in the ratio. It is important to
bear in mind that absence of statistical significance does not
necessarily imply absence of biological relevance. For instance,
more efficient intracellular degradation of some misfolded proteins
could prevent detection of an altered ratio of secreted to
intracellular COL4A1 for some mutations. Alternatively, these
data could indicate a third pathogenic mechanism whereby
mutant proteins are secreted and exert a detrimental extracellular
effect. In support of such a mechanism, the COL4A1
M1016V
mutation occurs within a putative binding site for the matricellular
glycoprotein SPARC (secreted protein acid and rich in cysteine)
[52] and could therefore act by disrupting protein-protein
interaction in the extracellular matrix.
These variants represent the first heterozygous mutations in
MEB/WWS patients. Although generally considered to be
recessive, the inheritance pattern in many MEB/WWS patients
is unknown. Phenotypic variability, reduced penetrance, and de
novo mutations can all explain how dominant mutations might
appear recessive in small families. Here, we observed non–
penetrance of the COL4A1
Q1316E mutation in the father of the
affected child. Families with COL4A1 mutations are only now
starting to be identified but apparent non-penetrance, and
asymptomatic carriers have already been reported [29,53].
Importantly, Col4a1-associated phenotypes in mice are not only
influenced by environmental factors but are also genetic context–
dependent, and reduced penetrance could reflect modifier loci.
Alternatively, genetic mosaicism of dominant collagen mutations
can explain asymptomatic carriers [54].
We identified mutations in two out of 27 CMD patients tested.
DNA was limiting and prevented us from also sequencing
COL4A2; however, evidence from mice and C. elegans support that
mutations in COL4A2 may cause phenotypes similar to those
resulting from mutations in COL4A1 [24,45,55]. It will be very
important in the future to determine whether the COL4A1 findings
extend to COL4A2. This could have an even broader relevance as
COL4A1 mutations are pleiotropic with variable penetrance and
expressivity from organ to organ. It is possible that COL4A1
mutations underlie CMD in patients with different, non-MEB/
WWS-like, subclasses of the disease. Based on our current data,
the most likely patients are those with mild myopathy and those
with clinical manifestations that overlap with some of the other
COL4A1-related phenotypes described in non-MEB/WWS syn-
dromes including porencephaly, renal disease and cerebrovascular
disease. Collectively, these findings provide the impetus for
COL4A1 and COL4A2 mutation analysis in further cohorts of
patients with CMD and/or congenital cerebral malformations.
COL4A1 mutations have been identified in families with a
spectrum of diseases affecting the cerebral vasculature, although
pathologies of the eyes, kidneys and muscles have also been
reported [21,22,25–29,31,33,56,57]. Notably, COL4A1 appears to
be an important genetic cause of porencephaly – a condition
usually diagnosed in infants and characterized by large cerebral
cystic cavities that communicate with the ventricles. Importantly,
the cortical malformations present in MEB/WWS and described
in the current manuscript are clinically and mechanistically
distinct from porencephalic cavities, which are predicted to result
from pre– or peri–natal hemorrhages in the germinal matrix.
Figure 9. The pathogenic mechanism by which Col4a1 mutation
causes MEB/WWS phenotypes is independent of dystroglycan
glycosylation. (A) Western blot analysis of total protein lysates from
quadriceps biopsy using antibody for dystroglycan precursor protein
(bottom) did not reveal a difference in dystroglycan precursor
expression between Col4a1
+/+ and Col4a1
+/Dex40 mice. To test for
differences in quantity or mobility (glycosylation) of a-dystroglycan and
b-dystroglycan, lysates were enriched for glycosylated proteins by WGA
binding. WGA-enriched fraction of quadriceps protein extracts did not
reveal differences in quantity or glycosylation of either a-dystroglycan
(top) or b-dystroglycan (middle) between Col4a1
+/+ and Col4a1
+/Dex40
mice. (B) Immunohistochemical labeling of muscle sections with
antibodies against the glycosylated form of a–dystroglycan (red) and
b-dystroglycan (green) show similar patterns of a– and b-dystroglycan
expression between Col4a1
+/+and Col4a1
+/Dex40 mice.
doi:10.1371/journal.pgen.1002062.g009
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phenotypic spectrum resulting from Col4a1 mutations in mice. We
propose that COL4A1 mutations in human patients will reflect the
pleiotropy observed in mice and will be involved in the
pathogenesis of diseases clinically distinct from those reported
previously. Optic nerve hypoplasia and cortical neuronal migra-
tion defects have not been described in human patients with
COL4A1 mutations and a role for COL4A1 or COL4A2 in MEB/
WWS-like diseases was not previously suspected. Interestingly, six
families with COL4A1 mutations and cerebrovascular disease also
had muscle cramps and CK elevation [28,33]. Although the
degree of CK elevation in Col4a1 mutant mice is less than that
observed in dystrophin-glycoprotein complex related disorders, it
is comparable to that seen in other types of dystrophies involving
extracellular matrix proteins, including collagen VI -associated
Bethlem myopathy and Ullrich CMD. While the exact mechanism
underlying myopathy in collagen VI-related disorders is unclear,
several lines of evidence suggest that mitochondrial dysfunction
may be an important player [58].
We show that genetic context is an important factor
contributing to the variable penetrance and severity of Col4a1-
related diseases and that the CAST/EiJ strain can modify
myopathy. These findings also imply that certain genetic contexts
might exacerbate myopathy and that COL4A1 mutations could
also cause severe CMD. Importantly, genetic modifiers can be
general or tissue specific and tissue-specific modification could
help explain how mutations in a single gene can contribute to such
diverse phenotypes. We also demonstrate that gene–environment
interactions contribute to phenotypic variability. We have
previously reported that cesarean delivery can reduce the risk of
perinatal intracerebral hemorrhages and here we show that
elevation in CK activity is exercise–dependent. Allelic differences
could also help explain variable expressivity and severity of
COL4A1-associated diseases between patients. For instance, a
mutation that affects heterotrimer assembly might have broader
effects than a mutation that specifically affects interactions with
cell surface receptors, growth factors or other extracellular matrix
molecules. Interestingly allelic differences are already emerging
pointing to genotype/phenotype correlations in some families
[28,33].
Pial basement membrane integrity is critical for normal cortical
development and insufficient COL4A1 in basement membranes
renders them prone to disruption. Breaches in the pial membrane
cause alterations in cortical neuronal distribution [17,59,60].
These are not intrinsic neuronal migration defects but are
secondary to disorganization of the cortical marginal zone, and
to defects in anchorage of glial endfeet and formation of the Cajal-
Retzius cell layer [16]. Reactive gliosis and increased GFAP
labeling may reflect broader breaches of the glia limitans including
the blood brain barrier [11,42]. Thus, while some structural
defects might be due to disruptions of the pial basement
membrane, other pathology might be attributed to disruptions of
vascular basement membranes and/or defects in blood brain
barrier function.
Understanding the precise mechanism underlying myopathy is
complicated by the presence of COL4A1 in basement membranes
of the sarcolemma, myotendonous junctions and neuromuscular
junctions. Notably, Col4a1 mutant mice have transient neuromus-
cular junction abnormalities that reportedly resolve by 3 weeks of
age [61]. Determination of the primary site of pathogenesis for
myopathy will likely require conditional expression of the Col4a1
mutation. However, evidence from other model systems suggests
that the primary mechanism is load-induced muscle fiber
detachment. For instance, the most common form of CMD
(MDC1A) is caused by mutations in the basement membrane
component laminin alpha 2 (LAMA2) [62] and in zebrafish with
mutations in the LAMA2 ortholog, muscle contractions lead to
muscle fiber detachment and loss [63]. This mechanism is
consistent with exercise-induced CK elevation in Col4a1 mutant
mice. This mechanism is also consistent with the observation that
C. elegans Col4a1 mutants die with ruptured basement membranes
shortly after muscle contractions begin [45,55]. A similar
mechanism in alveolar basement membranes could also explain
why newborn Col4a1 mutant mice have respiratory distress
immediately after starting to breathe [22].
Thus, myopathy resulting from mutations in basement mem-
brane components LAMA2 and COL4A1 might share a common
pathogenic mechanism whereby contraction-induced load leads to
muscle fiber detachment. Given this potential shared mechanism
and the phenotypic variability of COL4A1 mutations, we propose
that MDC1A patients that are negative for LAMA2 mutations are
suitable candidates for screening for mutations in COL4A1 and
COL4A2. Importantly, if a component of the pathology is
secondary to deleterious consequences of compromised blood
brain barrier and load-induced myopathy, there is the potential for
therapeutic interventions to blunt the severity of this devastating
disease. For example, conditions that promoted protein folding
and increased COL4A1 secretion in C. elegans mutants were able to
rescue muscle contraction-induced basement membrane disrup-
tions and promoted viability and survival [55]. Thus, chemical
chaperones, or other methods to promote protein folding, might
have therapeutic potential in human patients and improve the
prognosis for MEB/WWS patients.
Materials and Methods
Ethics statement
Animals. Experiments were conducted in compliance with
protocols approved by the Institutional Animal Care and Use
Committee at University of California in San Francisco.
Human patients. Written, informed consent was obtained
from the subjects or their legal guardians. The Institutional
Review Boards of Beth Israel Deaconess Medical Center and
Children’s Hospital Boston and the UCSF Committee on Human
Research approved this study.
Retinal analyses
Heads were equilibrated in 20% sucrose in phosphate buffered
saline (PBS) overnight at 4uC, embedded in OCT compound
(Sakura Finetek), and flash frozen using dry ice/ethanol. For each
genotype we analyzed six eyes at E14 and E16 and eighteen eyes
at E18. For each eye, at least 3 position-matched, transverse
sections (20 mm) were co-labelled with antibodies against Islet-1
(1:10, Developmental Studies Hybridoma Bank 39.4D5sup and
laminin (1:1000, Abcam), or Islet-1 and activated Caspase-3
(1:1000, R&D Systems). Sections were blocked (Tris-buffered
saline with 0.1% Triton-X (TBST) containing 5% normal goat
serum (Invitrogen)) for 1 hour at room temperature (RT) and
washed twice for 2 min with TBS. Labeling was performed in TBS
containing 3% BSA (Sigma) overnight at 4uC. Sections were
incubated with Alexa Fluor 488 goat anti-mouse and Alexa Fluor
594 goat anti-rabbit secondary antibodies (1:1000, Invitrogen) for
2 hours at RT and cover-slipped with Vectashield Hard Set with
DAPI (Vector Labs).
Cerebral analyses
Adult brains were fixed by trans-cardiac perfusion with 4%
paraformaldehyde (PFA) in 0.1 M sodium phosphate, pH 7.4 then
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ing as described above. For Nissl staining, coronal sections (25 mm)
were hydrated for 5 min in buffer (0.2% sodium acetate, 0.3%
glacial acetic acid) then incubated for 10 min in Nissl stain (0.02%
cresyl violet in buffer). Sections were washed in water (262 min)
and de-stained for 15 sec (0.3% glacial acetic acid in 70% ethanol)
before being dehydrated, cleared in xylene and cover-slipped with
Permount (Fisher).
For GFAP and NeuN immunostaining, sections were incubated
in 1% H202 in PBS for 15 min, washed in PBS, blocked in PBS
containing 5% NGS, 0.1% Triton-X, and 1% BSA in PBS for
1 hour at RT. Sections were incubated with anti-GFAP antibody
(1:500, Chemicon) or anti-NeuN antibody (Chemicon 1:500)
overnight at 4uC, washed in PBS containing 0.1%Triton-X, and
incubated for 2 hr with biotinylated goat anti-rabbit or goat anti-
mouse antibody (1:500, Vector Labs). Sections were then
incubated in avidin-biotin solution (Vector Labs) for 90 min and
immunoreactivity was visualized by treating sections with
diaminobenzidine (DAB, Vector Labs). Sections were dehydrated,
cleared in xylene and cover-slipped with Permount (Fisher).
For BrdU labeling, pregnant mice were injected with BrdU
(50 mg/kg) at gestational days 14, or 16. At P0, heads were fixed
in 4% PFA for 4 hr, embedded in OCT, snap frozen in dry ice/
ethanol bath. Cryosections (25 mm) were incubated in sodium
citrate buffer (10 mM sodium citrate, pH 6.0, 0.05% Tween-20)
for 30 min starting at 90uC and allowed to cool, rinsed in water,
incubated in 1 M HCl containing 0.2 mg/ml pepsin for 10 min at
RT, in 2 N HCl for 20 min at 37uC. Sections were then washed
and labeled with anti-BrdU (1:30, Accurate Chemical) and
biotinylated goat anti-rat secondary (1:500, Vector Labs). For
laminin immunolabeling of P0 brains, heads were processed as
described in the retinal analyses section and 20 mm coronal
sections were immunolabeled with anti- laminin antibody (1:1000,
Abcam).
Muscle analyses
Peak grip force was determined using a Grip Strength Meter
(Columbus Instruments) and using the average from 3 consecutive
trials on each animal. For CK measurements, blood was drawn
before and after exercise from the tail vein in a hematocrit tube,
centrifuged for 5 min, and the serum was collected. CK activity
was measured using CK-NADP assay (Raichem) and a microplate
reader (Biorad). Exercise was 30 minutes with a 15u downhill
grade on a treadmill equipped with a shock plate (Columbus
Instruments). Animals were started at 7 m/min and increased
3 m/min every 2 min until maximum of 16 m/min speed was
reached. Non-peripheral nuclei were evaluated in quadriceps and
tibialis anterior muscles dissected and frozen in liquid nitrogen-
cooled isopentane. Cryosections (8 mm) were stained with
hematoxylin and eosin for histopathology or labeled with anti-
pan laminin antibody (Sigma), followed by an anti-rabbit
AlexaFluor-488 secondary antibody, and the nuclei were labeled
with DAPI. The observers were masked to genotypes and counted
between 2000–5000 fibers per animal.
For dystroglycan enrichment and immunoblotting, quadriceps
muscle biopsy (100 mg) was homogenized in TBS (pH 7.5)
containing 1% Triton-X and protease inhibitors (Thermo
Scientific Pierce). The soluble fraction was incubated overnight
at 4uC with 200 ul of wheat germ agglutinin (WGA)-agarose beads
(Vector Laboratories) to enrich for glycosylated proteins. Beads
were washed three times with 1 ml TBS containing 0.1%Triton-X
and protease inhibitors (Thermo Fisher) and were boiled in SDS-
PAGE loading buffer for 5 minutes. Proteins (50 ml) were
separated on 10% SDS-PAGE and transferred to polyvinylidene
fluoride (PVDF) membranes (BioRad). Membranes were blocked
for 2 hours at room temperature in 5% non-fat milk in TBS
containing 0.1% Tween-20, incubated overnight with a mouse
monoclonal anti- a-dystroglycan antibody recognizing the glyco-
sylated form of a-dystroglycan (IIH6; 1:1000, Millipore), or rabbit
polyclonal anti- b-dystroglycan antibody (raised against the C-
terminus of dystroglycan precursor; 1:400, Santa Cruz) diluted in
blocking buffer. Membranes were washed in TBS containing 0.1%
Tween-20, incubated 2 hours at room temperature with horse-
radish peroxidase-conjugated secondary antibody raised in donkey
(anti-mouse IgM, and anti-rabbit IgG, respectively; 1:10 000,
Jackson Immunoresearch) diluted in blocking buffer. Immunore-
activity was visualized using chemiluminescence (SuperSignal
West Pico Chemiluminescent Substrate, Thermo Scientific).
For immunostaining, muscle cryosections (25 mm) were incu-
bated with either b-dystroglycan (1:150) or with a-dystroglycan
(1:400) antibody diluted in blocking buffer (10% normal donkey
serum, 0.2% BSA in PBS containing 0.1% Triton-X) overnight at
4uC and incubated with Alexa Fluor 488 conjugated donkey anti-
rabbit (Invitrogen) or cy5- conjugated donkey anti-mouse IgM
(Jackson Immunoresearch).
For COL4A1 immunolabeling, muscle cryosections (25 mm)
were fixed in acetone for 10 min, rinsed in TT buffer (50 mM
Tric-HCl, pH 7.4, 0.1% Tween-20), incubated in acid solution
(0.1 M KCl/HCl, pH 1.5), washed three times in TT buffer and
incubated for an hour in blocking buffer (10% normal donkey
serum and 2 mg/ml BSA in Tris buffer). Sections were then
incubated with rat anti- COL4A1 (H11) monoclonal antibody
(1:200, Shigei Medical Research Institute, Japan) diluted in TT
buffer overnight at 4uC and for 1 hour with Alexa Fluor 488
conjugated donkey anti-rat secondary antibody (Invitrogen) and
cover-slipped using mowiol mounting medium (Calbiochem).
Microscopy
Images were captured using an AxioImager M1 microscope
equipped with an AxioCam MRm digital camera for fluorescence
or AxioCam ICc3 for brightfield and AxioVision software (Zeiss).
Human analyses
Genomic DNA (10 ng/mL) sequencing was performed using
ABI BigDye v3.1 and analyzed using Sequencher software (Gene
Codes Corporation). Control samples are from ethnically matched
adults with no history of neurological disease.
Functional analysis of human mutations
HT1080 Human fibrosarcoma cells were transfected using
Superfect reagent (Qiagen) with the expression vector pReceiver–
M02 vector (GeneCopoeia) containing a CMV promoter up-
stream of GFP (to evaluate transfection efficiency), wild-type
Col4a1 or mutant Col4a1 cDNA cloned and a neomycin resistance
cassette, allowing stably transfected cells to be selected using G418
(Invitrogen). After 12 days of G418 selection (600 mg/ml),
individual surviving clones were isolated and expanded in presence
of 600 mg/ml of G148.
Stably transfected HT1080 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with penicillin,
streptomycin, nonessential amino acids, glutamine, sodium
pyruvate, G418 (250 mg/ml for maintenance), 10% Fetal Bovine
Serum (FBS) and ascorbic acid (50 mg/ml) at 37uC in 5% CO2 in
a humid atmosphere until they reach 80–90% confluence. Then,
cells were serum-deprived for 24 hours under the same culture
conditions and harvested and protein were extracted from
HT1080 cells using cell extraction buffer containing 0.05 M
Tris-HCl pH 8.0, 0.15 M NaCl, 5.0 mM EDTA, 1% NP-40, and
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(13000 rpm, 20 min at 4uC), the soluble fraction of the whole
cell lysate was collected for subsequent Western blot analysis. The
conditioned medium was collected at the same time and
supplemented with protease inhibitors.
Determination of protein concentration in the soluble fraction
wasperformedusinga DCproteinassay(BioRad) and 45 ugoftotal
protein were separated on a 4–15% gradient SDS-PAGE under
non-reducing conditions and transferred to polyvinylidene fluoride
(PVDF) membranes (BioRad). For the conditioned medium, the
volume loaded on the gel was adjusted based on the protein
concentration of the soluble fraction, which is assumed to reflect the
number of cells for a given sample. Membranes were blocked for
2 hours at room temperature in 5% non-fat milk in TBS containing
0.1% Tween-20, and overnight at 4uC in 3% BSA in TBS.
Membranes were then incubated with rat anti- COL4A1 (H11)
monoclonal antibody (1:100, Shigei Medical Research Institute,
Japan) in 1% BSA in TBS for 3 hours at room temperature and
werewashedinTBScontaining0.1%Tween-20,incubated2 hours
at room temperature with horseradish peroxidase-conjugated
secondary antibody raised in donkey (anti-Rat IgG 1:10 000,
Jackson Immunoresearch) diluted in 5% non-fat milk in TBS
containing 0.1% Tween-20. Immunoreactivity was visualized using
chemiluminescence (SuperSignal West Pico Chemiluminescent
Substrate, Thermo Scientific). Densitometric analysis was per-
formed on low exposure images using the NIH Image J software
(National Institutes of Health). For quantitative analysis of the ratio
of secreted to intracellular mutant COL4A1 protein, the amount of
COL4A1 detected in the conditioned medium was divided by the
amount of intracellular COL4A1 normalized with actin.
Statistical analyses
In experiments where two groups were compared, samples were
compared by a Student’s T-test with p,0.05 considered significant.
In experiments where more than two groups were compared,
samples were analyzed by one-way ANOVA followed by a Tukey’s
post hoc test with p,0.05 considered significant. For calculation of
apoptotic index, one E18 Col4a1
+/Dex40 eye had an extremely high
apoptotic index (12.9)that was considered an outlier by Grubbs’test
(p,0.01 vs. all mutants and Z=2.93248; vs. all samples
Z=3.26997) and was removed from subsequent statistical analyses.
Supporting Information
Figure S1 Col4a1
+/Dex40 mice have hippocampal neuronal
localization defects. Representative cresyl violet stained coronal
sections from adult Col4a1
+/+ (A–D) and position-matched
Col4a1
+/Dex40 (E–H) brains revealed subtle but consistent neuronal
localization defects in hippocampi of mutant mice. Regions of the
CA1 (red boxes in A and E), CA3 (black boxes in A and E) and
dentate gyrus (white boxes in A and E) are enlarged in B and F, C
and G, and D and H, respectively. All mutant mice (n=6) had
hippocampal defects that included focal distortions (red box in E,
compared to A) as well as diffusion of pyramidal cell layers in the
CA1 (F, compared to B) and CA3 (G, compared to C) regions and
granular cell layers in the dentate gyrus (H, compared to D). Scale
bars: A and E, 500 mm; B–D and F–H, 100 mm.
(TIF)
Figure S2 Presence of reactive astrocytes in the brain of
Col4a1
+/Dex40 mice. Representative coronal brain sections from
adult Col4a1
+/+ (A–C) and position matched Col4a1
+/Dex40 (D–F)
mice labeled with anti-GFAP antibody revealed the presence of
reactive astrocytes. Compared to Col4a1
+/+ brains (A), Col4a1
+/Dex40
mice had increased GFAP labeling in the cortex (D). Higher
magnification images revealed increased labeling in Col4a1
+/Dex40
mice (E compared to B) and the astrocytic morphology of the
labeled cells. Increased labeling was also detected in Col4a1
+/Dex40
hippocampi compared to Col4a1
+/+ (F compared to C). Scale bars:
A, C, D, F 500 mm; B and E, 100 mm.
(TIF)
Figure S3 COL4A1 is present in skeletal muscle basement
membrane of Col4a1
+/+ and Col4a1
+/Dex40 mice. Immunohisto-
chemical labeling of muscle sections with antibodies against
COL4A1 confirmed that COL4A1 is present in Col4a1
+/+ (A) and
Col4a1
+/Dex40 (B) skeletal muscle basement membrane and
revealed that the mutant basement membrane appeared to label
less uniformly and less intensely.
(TIF)
Figure S4 Brain imaging of patients 1 and 2. Brain magnetic
resonance imaging in patient 1 (A–B), a normal control (C–E) and
patient 2 (F–G). Patient 1 has a typical WWS phenotype with a
severe cobblestone-type cortical malformation with a smooth brain
surface that resembles lissencephaly, a thin and discontinuous
laminar heterotopia just below the cortex (arrow in A), diffusely
abnormal white matter (asterisk in A), thin brainstem, enlarged
tectum (arrowhead in B), moderate kink at the midbrain-pons
junction (arrow in B), severe cerebellar hypoplasia (seen in both A
and B), and enlarged posterior fossa. The cortex is ,10 mm thick
withan irregular gray-white border (A), while classic lissencephaly is
typically 12–20 mm thick with a smooth gray-white border. The
brainstem kink is less severe than typical for WWS. Patient 2 has a
less severe MEB phenotype with diffuse cobblestone-type cortical
malformation that appears thicker over the frontal lobes (best seen
in G), diffuse abnormal white matter signal (asterisk in G),
moderately enlarged lateral ventricles (F and G) and thin brainstem
with flat pons (arrow in F). The gyral pattern is irregular and
resembles polymicrogyria, but no actual microgyri are seen. These
are patients LP93-014 and LP90-029 from the Dobyns database.
Parts A and B are modified from Figure 1 in [Kanoff, et al]. [Kanoff
RJ, Curless RG, Petito C, Falcone S, Siatkowski RM, et al., (1998)
Walker-Warburg syndrome: neurologic features and muscle
membrane structure. Pediatr Neurol 18:76–80.].
(TIF)
Table S1 Sequencing primers for COL4A1.
(PDF)
Table S2 Non-Synonymous coding variants identified.
(PDF)
Table S3 Synonymous coding variants identified.
(PDF)
Table S4 Intronic variants identified.
(PDF)
Text S1 Clinical details of human patients.
(DOC)
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